The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)
Open accessAbstract
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist. Patients with a diagnosis of probable VaD and Mini Mental State Examination total scores between 10 and 22 were eligible for inclusion. Primary efficacy parameters were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Clinical Global Impression of Change (CGI-C). A total of 579 patients were randomized and 548 patients with at least one post-baseline efficacy assessment qualified for the intent-to-treat analysis. At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of -1.75 points (95% confidence intervals -3.023 to -0.49) and a median of 2 points between the two groups, while CGI-C ratings showed no significant differences between treatment groups. A total of 77% of all memantine-treated patients experienced adverse event, versus 75% of the placebo-treated patients, dizziness being the most frequent adverse event (11% versus 8%, respectively). Memantine was well tolerated and safe.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rivastigmine has been less well studied, but beneficial effects on an executive measure were found in a 22-month, open-label controlled (n=16) study409 and in a double-blind placebo-controlled trial targeting vascular cognitive impairment, no dementia (n=50).405”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Evaluation of Experiments with Adaptive Interim Analyses
Bauer, P., & Kohne, K. (1994) · Biometrics · doi:10.2307/2533441 · Cited by 865
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829 · cited 1×
“In Asia and some developing countries, the prevalence of VaD may even equal or exceed that of AD (Yoshitake et al., 1995).”
BackgroundOrgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Self-citationA new rating scale for dementia syndromes
Gottfries, C.-G., Bråne, G., Gullberg, B., & Steen, G. (1982) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(82)90031-0 · Cited by 280
Danysz, W., Parsons, C. G., MÖbius, H.-J., StÖffler, A., & Quack, G. (2000) · Neurotoxicity Research · doi:10.1007/bf03033787 · Cited by 263
Self-citationSpiegel, R., Brunner, C., Ermini‐Fünfschilling, D., Monsch, A., Notter, M., Puxty, J., & Tremmel, L. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb02897.x · Cited by 219
Glutamate transmission and toxicity in alzheimer's disease
Greenamyre, J. T., Maragos, W. F., Albin, R. L., Penney, J. B., & Young, A. B. (1988) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(88)90102-9 · Cited by 197
Research works printed but not linked: 8
- Forette, 1991, Aging, 3, 373???382
- Gottfries, 1982, Arch Gerontol Geriatr, 1, 311???330
- Hachinski, 1994, Dementia, 5, 130???132
- Hamilton, 1960, J Neurol Neurosurg Psychiatry, 23, 56???62
- Mohs, 1988, Psychopharmacol Bull, 24, 627???628
- Pantoni, 1999, Alzheimer Dis Assoc Disord, 13, S49???S54
- Rom??n, 1993, Neurology, 43, 250???260
- Winblad, 1999, Int J Geriatr Psychiatry, 14, 135???146
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Pantoni, L. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70104-6 · Cited by 3,405
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
(2014) · International Journal of Stroke · doi:10.1111/ijs.12374_18 · Cited by 1,166
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Metadata
- Authors
- Wilcock, G., M??bius, H. J., & St??ffler, A.
- Affiliations
- Frenchay Hospital (GB)
- ORCID
- Wilcock, G.
- Venue
- International Clinical Psychopharmacology
- Published
- 2002-11
- Volume
- 17
- Issue
- 6
- Pages
- 297-305
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1990057142
- Cited by
- 381
- References
- 25
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 47 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 8 · 2015: 14 · 2014: 15 · 2013: 15 · 2012: 10
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.uwe.ac.uk
- Licence
- cc-by
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UWE Research Repository (UWE Bristol) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- memantine, vascular dementia, NMDA receptor antagonists, cognitive function, drug safety, adverse events, dizziness, Mini-Mental State Examination, ADAS-Cog, Clinical Global Impression of Change, treatment efficacy
- MeSH terms
- Aged, Aged, 80 and over, Antiparkinson Agents, Cognition, Dizziness, Double-Blind Method, Female, Humans, Male, Memantine, Mental Status Schedule, Placebos, Dementia, Vascular, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). https://app.cochat.ai/papers/10.1097/00004850-200211000-00005
- The paper
- Wilcock, G., M??bius, H. J., & St??ffler, A. (2002). A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200211000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.